- Feb 10 Sun 2013 22:59
-
新年快樂！
- Dec 09 Sun 2012 20:46
-
關於咬合板的費用...
一般地區醫院以上牙醫師 經健保局核可後 可以依健保規定申報 但是診所仍不能申報
至於後續處理費用, 有的醫師會依據複雜度或專業需求予以收費
而在保固期(硬式:一年)內, 如果損毀或是遺失, 就必須自費了！ 費用依各醫療院所不同而不同！！
至於軟式咬合板 較易損毀 一般重做幾乎都需付費！！
至於後續處理費用, 有的醫師會依據複雜度或專業需求予以收費
而在保固期(硬式:一年)內, 如果損毀或是遺失, 就必須自費了！ 費用依各醫療院所不同而不同！！
至於軟式咬合板 較易損毀 一般重做幾乎都需付費！！
- Mar 04 Sun 2012 17:15
-
【蘋果日報 2012/03/02】女植牙燙傷醫判罰18萬
- Feb 15 Wed 2012 22:48
-
醫病關係是互動的不是只有患者...
一般而言 手術 包括拔牙 都會有些微至明顯不等的瘢痕 就是傷疤
因此 多多少少會造成 患處緊繃 或是 感覺不太一樣的情形
這是人體的正常反應
為了減少瘢痕 有很多術式和方式 希望有幫助 但也不是每個人的效果都一樣
因此 多多少少會造成 患處緊繃 或是 感覺不太一樣的情形
這是人體的正常反應
為了減少瘢痕 有很多術式和方式 希望有幫助 但也不是每個人的效果都一樣
- Oct 30 Sun 2011 21:39
-
口腔衛生教育須確實紮根.. 不論是民眾 還是 醫師...
因為我是口腔外科的專科醫師, 接觸的患者多是由外院轉介或是已經有不舒服的疼痛的民眾. 然而, 在接觸質樸真誠的民眾之後, 卻發現資訊發達的年代, 卻仍有近6成的人沒有正確的認知, 或將近5成的人對牙醫師的治療有恐懼... 回想起來, 真是令人感傷與不捨.
不斷的思考問題的起源, 卻發現是"教育(資訊)"出了問題！！從基本的口腔衛生習慣, 牙結石的清潔, 蛀牙的修復, 假牙的製作, 牙周的照顧, 該拔的牙齒或是植牙的概念... 通通都出了些問題...
有患者還在問我洗牙好不好, 或是自己不洗牙也堅持不讓自己的小孩洗牙... 有的堅持留住"柳絮隨風擺"般的牙齒, 或是把拔掉有問題的牙齒當成醫師想要賺錢的做法... 有的是沒有辦法做合理的固定假牙, 卻不顧學理的請齒模師做牙齒... 有的是怕酸 怕痛 怕腫 怕沒牙齒難看, 卻不願意接受治療, 直到狀況變差... 有些是相信一些廣告, 卻怎麼也不相信醫師的指導... 還有一些則是把牙醫師當成機器, 他(她)想做什麼就得怎麼做...
林林總總的怪現象, 讓第一線的職業醫師很是頭痛！！那問題到底該怎麼解決呢？？ 個人覺得得由三方面著手
不斷的思考問題的起源, 卻發現是"教育(資訊)"出了問題！！從基本的口腔衛生習慣, 牙結石的清潔, 蛀牙的修復, 假牙的製作, 牙周的照顧, 該拔的牙齒或是植牙的概念... 通通都出了些問題...
有患者還在問我洗牙好不好, 或是自己不洗牙也堅持不讓自己的小孩洗牙... 有的堅持留住"柳絮隨風擺"般的牙齒, 或是把拔掉有問題的牙齒當成醫師想要賺錢的做法... 有的是沒有辦法做合理的固定假牙, 卻不顧學理的請齒模師做牙齒... 有的是怕酸 怕痛 怕腫 怕沒牙齒難看, 卻不願意接受治療, 直到狀況變差... 有些是相信一些廣告, 卻怎麼也不相信醫師的指導... 還有一些則是把牙醫師當成機器, 他(她)想做什麼就得怎麼做...
林林總總的怪現象, 讓第一線的職業醫師很是頭痛！！那問題到底該怎麼解決呢？？ 個人覺得得由三方面著手
- Aug 07 Sun 2011 09:44
-
牙醫師口腔黏膜檢查教育訓練課程筆記
講者: 黃裕峰 副教授 / 筆記: 陳怡睿 講師
【1】口腔內正常的黏膜表現
1. Torus (palatal ; lingual) / Exostosis
2. Fordyce's granule : 黃色小點 , 可能出現在頰側 , 也可能出現在唇緣
【1】口腔內正常的黏膜表現
1. Torus (palatal ; lingual) / Exostosis
2. Fordyce's granule : 黃色小點 , 可能出現在頰側 , 也可能出現在唇緣
- Aug 06 Sat 2011 00:04
-
【自由電子報 2011/8/5 17:20】7歲得口腔癌 醫：全台最年幼
7歲得口腔癌 醫：全台最年幼 【2011/8/5 17:20】
〔中央社〕7歲廖小弟乳牙換牙後，傷口遲遲未癒合，就醫檢查後才赫然發現罹患口腔癌。醫師說，這是全台最年幼的口腔癌患者，並提醒傷口若超過3週沒有癒合，應儘速就醫。
廖小弟年初乳牙掉落後，傷口一直沒有癒合，後來換牙處還出現膿包狀突起，就醫確診是口腔癌後，經手術切除腫瘤後，目前已經出院。
「兒童罹患口腔癌案例很罕見」，台北慈濟醫院口腔顎面中心主任夏毅然說，國內口腔癌好發於30歲到45歲的青壯年族群，廖小弟是全球第2年幼的口腔癌患者，也是全亞洲最年幼的病例，目前還無法確定其病因。
夏毅然說，廖小弟的口腔癌發生在下顎牙齦，靠近頸部淋巴結，因此手術切除腫瘤時，要避免傷到「細如髮絲」的下顎神經，難度頗高。日後會定期追蹤檢查，讓他的臉部發育能左右對稱，成年後再進行人工植牙。
夏毅然表示，許多口腔癌病人當初都誤以為是牙周病或普通破皮，反而錯過治療的黃金時機。他提醒，口內傷口如果超過2到3週沒有癒合，務必要就醫檢查。
〔中央社〕7歲廖小弟乳牙換牙後，傷口遲遲未癒合，就醫檢查後才赫然發現罹患口腔癌。醫師說，這是全台最年幼的口腔癌患者，並提醒傷口若超過3週沒有癒合，應儘速就醫。
廖小弟年初乳牙掉落後，傷口一直沒有癒合，後來換牙處還出現膿包狀突起，就醫確診是口腔癌後，經手術切除腫瘤後，目前已經出院。
「兒童罹患口腔癌案例很罕見」，台北慈濟醫院口腔顎面中心主任夏毅然說，國內口腔癌好發於30歲到45歲的青壯年族群，廖小弟是全球第2年幼的口腔癌患者，也是全亞洲最年幼的病例，目前還無法確定其病因。
夏毅然說，廖小弟的口腔癌發生在下顎牙齦，靠近頸部淋巴結，因此手術切除腫瘤時，要避免傷到「細如髮絲」的下顎神經，難度頗高。日後會定期追蹤檢查，讓他的臉部發育能左右對稱，成年後再進行人工植牙。
夏毅然表示，許多口腔癌病人當初都誤以為是牙周病或普通破皮，反而錯過治療的黃金時機。他提醒，口內傷口如果超過2到3週沒有癒合，務必要就醫檢查。
- Jul 27 Wed 2011 17:45
-
植牙手術前的身體評估 (Dr.夏毅然 2011/07/24 台中榮總演講筆記)
＊ Contraindications for Surgical Placement of Implants (植牙手術的禁忌症)
(1) 主要禁忌症:
=> 1. Bisphosphonate therapy (特別是針劑注射的患者, 如 Zometa <zoledronic acid> ) / 2. Osteopetrosis / 3. Fibrous dysplasia / 4. Chronic diffuse sclerosing osteomyelitis / 5. Osseous dysplasia / 6. Arm paralysis / 7. Debilitating arthritis / 8. Cerebral palsy / 9. Mental retardation / 10. Parkinson's disease
(2) Temporary:
(1) 主要禁忌症:
=> 1. Bisphosphonate therapy (特別是針劑注射的患者, 如 Zometa <zoledronic acid> ) / 2. Osteopetrosis / 3. Fibrous dysplasia / 4. Chronic diffuse sclerosing osteomyelitis / 5. Osseous dysplasia / 6. Arm paralysis / 7. Debilitating arthritis / 8. Cerebral palsy / 9. Mental retardation / 10. Parkinson's disease
(2) Temporary:
- Jul 24 Sun 2011 22:10
-
簡述水平或阻生齒的拔牙過程
很多人都會問到底智齒要不要拔?要怎麼拔?長不出來的要怎麼拔?
現在先針對拔阻生智齒的方式做一簡單的文字說明...
Step1. 消毒: 口內CHX漱口水 ＋ 優碘(BI)
顏面部位: 優碘(BI), 範圍涵蓋洞巾露出的區域(鼻尖到下巴)
現在先針對拔阻生智齒的方式做一簡單的文字說明...
Step1. 消毒: 口內CHX漱口水 ＋ 優碘(BI)
顏面部位: 優碘(BI), 範圍涵蓋洞巾露出的區域(鼻尖到下巴)
- Jun 12 Sun 2011 08:45
-
關於顳顎關節的治療...
最近常有朋友詢問關於顳顎關節的治療..大致說明如下...
一般, 症狀必須區分是 肌肉疼痛/關節問題/或是兩種合併甚至是更複雜的問題
再來, 必須儘可能找出造成問題的原因, 如 壓力/磨牙/飲食習慣/不良習慣/齒列問題/關節問題/全身性疾病...
治療則區分: 心情治療(放鬆/休息)/藥物治療(止痛/肌肉鬆弛劑)/物理治療(熱敷/紅外線/雷射)/針灸.../軟or硬式咬合板...
一般, 症狀必須區分是 肌肉疼痛/關節問題/或是兩種合併甚至是更複雜的問題
再來, 必須儘可能找出造成問題的原因, 如 壓力/磨牙/飲食習慣/不良習慣/齒列問題/關節問題/全身性疾病...
治療則區分: 心情治療(放鬆/休息)/藥物治療(止痛/肌肉鬆弛劑)/物理治療(熱敷/紅外線/雷射)/針灸.../軟or硬式咬合板...
- Jul 25 Sat 2009 19:40
-
(2009725新聞稿)智齒新用 恢復青少年期缺牙空間
ps: 個人將本文的重點標示出來
智齒新用 恢復青少年期缺牙空間
文／蔡靜宜（行政院衛生署台中醫院牙科醫師）
很多家長認為，兒童換牙是從門牙開始，所以當小朋友下顎門牙開始搖動時，一般會認為：「我家寶貝從現在開始換恆牙了。」其實成人恆牙早在下顎乳門牙還沒開始搖動時，可能就已在現存乳牙齒列的最後面，先長出第一顆恆牙了。
這顆牙齒也就是所謂的「第一大臼齒」，因為約在兒童6歲的時候萌發，所以此顆牙又稱為「6歲齒」。在齒列中，上下左右總共有4顆第一大臼齒，它們佔有50%的咀嚼功能，所以有極重要的地位。
因為恆牙第一大臼齒剛萌出時，位在齒列的最後面，往往容易被疏忽，小朋友在刷牙時，還不知道口腔內已經長出恆牙了，因而在刷牙時，沒把它刷乾淨，導致第一大臼齒比較容易蛀牙。如果一直置之不理，等到12至13歲時，才發現這顆「乳牙」怎麼沒有換？或是等到牙痛時，才請牙醫師診治，得知原來它是恆牙時，往往已是嚴重蛀牙，需要接受根管治療，甚至是拔除。
如果一個青少年需拔除第一大臼齒，該怎麼補救？由於青少年臼齒的牙冠尚未完全萌出，所以不適合做傳統固定假牙。必要時，大多改採活動假牙，但是活動假牙戴起來不方便，咀嚼能力較差，且有異物感，所以青少年配戴意願不高；植牙同樣也不適合應用於正在發育的青少年。
這時便可考慮利用矯正的方式，把第二大臼齒移動到缺空的第一大臼齒位置，也就是利用第二大臼齒來取代第一大臼齒。這時期已存在齒槽骨內的智齒牙胚，會因第二大臼齒移到第一大臼齒而自動往前遞補第二大臼齒的空缺。
等到17至18歲時，這顆智齒就會在原來第二大臼齒的位置萌出，自然而然由第二大臼齒、智齒，往前取代原來的第一大臼齒、第二大臼齒，彌補缺牙空間，就不需要做假牙。
這種「遞補—取代」的治療方式，最重要的是掌握適當時機，也就是約在14歲左右，智齒牙根尚未發育前。
兒童應該每3到6個月定期做口腔檢查，若家長發現下顎乳門牙已經開始搖動，準備換牙時，必須注意齒列最後面可能已有恆牙—第一大臼齒萌出。家長須提醒小朋友刷牙時，務必要刷到全部的牙齒。若發現有蛀牙，則須儘早就醫。
智齒新用 恢復青少年期缺牙空間
文／蔡靜宜（行政院衛生署台中醫院牙科醫師）
很多家長認為，兒童換牙是從門牙開始，所以當小朋友下顎門牙開始搖動時，一般會認為：「我家寶貝從現在開始換恆牙了。」其實成人恆牙早在下顎乳門牙還沒開始搖動時，可能就已在現存乳牙齒列的最後面，先長出第一顆恆牙了。
這顆牙齒也就是所謂的「第一大臼齒」，因為約在兒童6歲的時候萌發，所以此顆牙又稱為「6歲齒」。在齒列中，上下左右總共有4顆第一大臼齒，它們佔有50%的咀嚼功能，所以有極重要的地位。
因為恆牙第一大臼齒剛萌出時，位在齒列的最後面，往往容易被疏忽，小朋友在刷牙時，還不知道口腔內已經長出恆牙了，因而在刷牙時，沒把它刷乾淨，導致第一大臼齒比較容易蛀牙。如果一直置之不理，等到12至13歲時，才發現這顆「乳牙」怎麼沒有換？或是等到牙痛時，才請牙醫師診治，得知原來它是恆牙時，往往已是嚴重蛀牙，需要接受根管治療，甚至是拔除。
如果一個青少年需拔除第一大臼齒，該怎麼補救？由於青少年臼齒的牙冠尚未完全萌出，所以不適合做傳統固定假牙。必要時，大多改採活動假牙，但是活動假牙戴起來不方便，咀嚼能力較差，且有異物感，所以青少年配戴意願不高；植牙同樣也不適合應用於正在發育的青少年。
這時便可考慮利用矯正的方式，把第二大臼齒移動到缺空的第一大臼齒位置，也就是利用第二大臼齒來取代第一大臼齒。這時期已存在齒槽骨內的智齒牙胚，會因第二大臼齒移到第一大臼齒而自動往前遞補第二大臼齒的空缺。
等到17至18歲時，這顆智齒就會在原來第二大臼齒的位置萌出，自然而然由第二大臼齒、智齒，往前取代原來的第一大臼齒、第二大臼齒，彌補缺牙空間，就不需要做假牙。
這種「遞補—取代」的治療方式，最重要的是掌握適當時機，也就是約在14歲左右，智齒牙根尚未發育前。
兒童應該每3到6個月定期做口腔檢查，若家長發現下顎乳門牙已經開始搖動，準備換牙時，必須注意齒列最後面可能已有恆牙—第一大臼齒萌出。家長須提醒小朋友刷牙時，務必要刷到全部的牙齒。若發現有蛀牙，則須儘早就醫。
- Jul 07 Tue 2009 21:08
-
Bisphosphonate-related osteonecrosis of the jaws (BRONJ)
整理by Dr.陳怡睿
Bisphosphonates prevent, reduce and delay cancer-related skeletal complications.
Bisphosphonate-related osteonecrosis of the jaws (BRONJ) was first reported by Marx (2003). This severe complication occurs most frequently in patients on intravenous bisphosphonates treatment for malignant diseases such as multiple myeloma or metastatic malignant disease, mainly breast cancer.
Many authors, however, consider that the benefits of bisphosphonate treatment in malignant disease generally outweigh any risks. Some cases of BRONJ have also been reported in patients on oral bisphosphonates treatment for osteoporosis but millions of patients are on oral bisphosphonates treatment for osteoporosis, and these oral drugs are helpful in preventing hip fractures in older women in particular.
BRONJ appears as a non‐healing exposed bone in the maxillofacial region and may affect patients undergoing intravenous cancer‐related bisphosphonate therapy or more rarely, patients treated with oral or IV bisphosphonates for osteoporosis.
The 2009 Position Paper retains the case definition of BRONJ:
1. The patient is or has been treated with a bisphosphonate.
2. Exposed bone has been present in the maxillofacial region for more than eight weeks; and
3. There is no history of radiation therapy to the jaws.
Specifically, the 2009 BRONJ Position Paper observes that the risk of developing BRONJ is linked to:
1. The potency the bisphosphonate used in therapy; and
2. The length of exposure to bisphosphonates.
Other factors that may increase the risk of developing BRONJ include:
1. A history of inflammatory dental disease, such as periodontal disease and dental abscesses;
2. Increased age;
3. Other systemic factors or conditions, such as renal dialysis, low hemoglobin, obesity and diabetes; and
4. In some cases, there may be a genetic predisposition to developing BRONJ.
The 2009 BRONJ Position Paper offers some strategies for preventing BRONJ in cancer patients treated with IV bisphosphonates.
1. Prior to initiation of cancer‐related IV bisphosphonate treatment, patients should have a thorough dental examination and complete the necessary procedures to achieve optimal periodontal health.
2. Given the long‐term biologic activity of IV bisphosphonates noted in the literature, the 2009 Position Paper suggests that alternative dosing regimens that reduce bisphosphonate exposure may be effective in decreasing the risk for BRONJ.
Pathogenesis
Bisphosphonates
1. inhibit the enzyme 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase,
2. block osteoclast protein prenylation, and thus
3. block osteoclast-mediated bone resorption. This predisposes to BRONJ.
Ruggiero and Drew described the elective involvement of the jaws compared to other bone sites and may be due to the healing of an open bone wound and that bisphosphonates are preferentially deposited in bones with high turnover rates as the jaws.
Incidence
BRONJ is far more frequently induced by intravenous bisphosphonates than by oral bisphosphonates. Hoff et al. found that 1.2% patients with breast cancer and 2.4% with myeloma on intravenous bisphosphonate treatment developed BRONJ. Wang et al. reported a slightly greater incidence both in myeloma (3.8%), in breast cancer (2.5%) and prostate cancer (2.9%). Recently Stumpe et al. found a global incidence of 0.94%.
Risk factors
Several studies have focussed on the risk factors for developing BRONJ. Treatment with high potency intravenous bisphosphonates such as zoledronic acid and pamidronate, and dental extractions, are important risk factors. The duration of bisphosphonate treatment, the number of infusions and the total infusion hours may also be risk factors for BRONJ.
Oral health appears not to be a risk factor for BRONJ. Obesity and smoking were recently associated with BRONJ. Delayed-onset BRONJ associated with zoledronic acid has also been described.
Genetic factors also influence the risk for BRONJ (single nucleotide polymorphism rs1934951 of the drug-metabolising enzyme cytochrome P450 CYP2C8).
New clinical forms of presentation
The main clinical signs and symptoms are pain, areas of exposed and necrotic bone with tooth mobility, mucosal swelling, erythema, and ulceration, abscesses and fistulas.
Diagnostic methods for assessing the extent of lesions
Computed Tomography (CT) scan vs. Magnetic Resonance Imaging (MRI)
Management
BRONJ is painful and difficult to treat. Management of BRONJ remains controversial. The consensus is to manage patients with BRONJ conservatively when at least 23–53% of patients achieve resolution of mucosal discontinuities. However, some patients need surgery. Hyperbaric oxygen (HBO) has been suggested and recommended by some authors as a complementary therapy.
Prevention
One prospective study found that the risk of BRONJ decreased after the implementation of preventive dental procedures and this was supported by another that showed a reduction in BRONJ incidence from 3.2% to 1.3% after a preventive programme.
Finally, the risk of BRONJ diminishes when the frequency of administration of bisphosphonates is reduced, so a reduced drug schedule may be a useful tool to prevent this severe adverse effect.
Bisphosphonates prevent, reduce and delay cancer-related skeletal complications.
Bisphosphonate-related osteonecrosis of the jaws (BRONJ) was first reported by Marx (2003). This severe complication occurs most frequently in patients on intravenous bisphosphonates treatment for malignant diseases such as multiple myeloma or metastatic malignant disease, mainly breast cancer.
Many authors, however, consider that the benefits of bisphosphonate treatment in malignant disease generally outweigh any risks. Some cases of BRONJ have also been reported in patients on oral bisphosphonates treatment for osteoporosis but millions of patients are on oral bisphosphonates treatment for osteoporosis, and these oral drugs are helpful in preventing hip fractures in older women in particular.
BRONJ appears as a non‐healing exposed bone in the maxillofacial region and may affect patients undergoing intravenous cancer‐related bisphosphonate therapy or more rarely, patients treated with oral or IV bisphosphonates for osteoporosis.
The 2009 Position Paper retains the case definition of BRONJ:
1. The patient is or has been treated with a bisphosphonate.
2. Exposed bone has been present in the maxillofacial region for more than eight weeks; and
3. There is no history of radiation therapy to the jaws.
Specifically, the 2009 BRONJ Position Paper observes that the risk of developing BRONJ is linked to:
1. The potency the bisphosphonate used in therapy; and
2. The length of exposure to bisphosphonates.
Other factors that may increase the risk of developing BRONJ include:
1. A history of inflammatory dental disease, such as periodontal disease and dental abscesses;
2. Increased age;
3. Other systemic factors or conditions, such as renal dialysis, low hemoglobin, obesity and diabetes; and
4. In some cases, there may be a genetic predisposition to developing BRONJ.
The 2009 BRONJ Position Paper offers some strategies for preventing BRONJ in cancer patients treated with IV bisphosphonates.
1. Prior to initiation of cancer‐related IV bisphosphonate treatment, patients should have a thorough dental examination and complete the necessary procedures to achieve optimal periodontal health.
2. Given the long‐term biologic activity of IV bisphosphonates noted in the literature, the 2009 Position Paper suggests that alternative dosing regimens that reduce bisphosphonate exposure may be effective in decreasing the risk for BRONJ.
Pathogenesis
Bisphosphonates
1. inhibit the enzyme 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase,
2. block osteoclast protein prenylation, and thus
3. block osteoclast-mediated bone resorption. This predisposes to BRONJ.
Ruggiero and Drew described the elective involvement of the jaws compared to other bone sites and may be due to the healing of an open bone wound and that bisphosphonates are preferentially deposited in bones with high turnover rates as the jaws.
Incidence
BRONJ is far more frequently induced by intravenous bisphosphonates than by oral bisphosphonates. Hoff et al. found that 1.2% patients with breast cancer and 2.4% with myeloma on intravenous bisphosphonate treatment developed BRONJ. Wang et al. reported a slightly greater incidence both in myeloma (3.8%), in breast cancer (2.5%) and prostate cancer (2.9%). Recently Stumpe et al. found a global incidence of 0.94%.
Risk factors
Several studies have focussed on the risk factors for developing BRONJ. Treatment with high potency intravenous bisphosphonates such as zoledronic acid and pamidronate, and dental extractions, are important risk factors. The duration of bisphosphonate treatment, the number of infusions and the total infusion hours may also be risk factors for BRONJ.
Oral health appears not to be a risk factor for BRONJ. Obesity and smoking were recently associated with BRONJ. Delayed-onset BRONJ associated with zoledronic acid has also been described.
Genetic factors also influence the risk for BRONJ (single nucleotide polymorphism rs1934951 of the drug-metabolising enzyme cytochrome P450 CYP2C8).
New clinical forms of presentation
The main clinical signs and symptoms are pain, areas of exposed and necrotic bone with tooth mobility, mucosal swelling, erythema, and ulceration, abscesses and fistulas.
Diagnostic methods for assessing the extent of lesions
Computed Tomography (CT) scan vs. Magnetic Resonance Imaging (MRI)
Management
BRONJ is painful and difficult to treat. Management of BRONJ remains controversial. The consensus is to manage patients with BRONJ conservatively when at least 23–53% of patients achieve resolution of mucosal discontinuities. However, some patients need surgery. Hyperbaric oxygen (HBO) has been suggested and recommended by some authors as a complementary therapy.
Prevention
One prospective study found that the risk of BRONJ decreased after the implementation of preventive dental procedures and this was supported by another that showed a reduction in BRONJ incidence from 3.2% to 1.3% after a preventive programme.
Finally, the risk of BRONJ diminishes when the frequency of administration of bisphosphonates is reduced, so a reduced drug schedule may be a useful tool to prevent this severe adverse effect.
